PRQR ProQR Therapeutics N.V. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1612940 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 15.91M | 18.91M | 6.51M | 3.59M | 1.33M |
| R&D expense | 44.73M | 36.36M | 25.15M | 50.87M | 42.22M |
| SG&A expense | 15.06M | 13.66M | 16.24M | 18.65M | 17.37M |
| Operating income | -43.45M | -30.47M | -31.86M | -65.16M | -57.21M |
| Interest expense | 929,000 | 1.08M | 1.20M | 5.13M | 3.40M |
| Pretax income | -42.16M | -27.96M | -27.81M | -64.11M | -60.68M |
| Income tax | 19,000 | -197,000 | -78,000 | 96,000 | 117,000 |
| Net income | -42.18M | -27.76M | -28.12M | -64.42M | -60.74M |
| EBITDA | — | — | — | — | -54.88M |
| EPS (basic) | -0.40 | -0.32 | -0.35 | -0.90 | -0.95 |
| EPS (diluted) | -0.40 | -0.32 | -0.35 | -0.90 | -0.95 |
| Weighted avg. shares (diluted) | 105.33M | 86.09M | 81.01M | 71.64M | — |
| Balance sheet | |||||
| Cash & equivalents | 92.41M | 149.41M | 118.92M | 94.78M | 187.52M |
| Receivables | 6.80M | 3.75M | — | 56.25M | — |
| Current assets | 100.13M | 153.84M | 120.99M | 154.46M | 191.48M |
| PP&E, netmay include right-of-use assets (IFRS) | 12.63M | 14.11M | 16.90M | 16.24M | 17.47M |
| Total assets | 112.76M | 167.96M | 137.88M | 171.32M | 209.58M |
| Current liabilities | 32.44M | 38.90M | 34.20M | 20.99M | 27.60M |
| Short-term debt | 4.87M | 4.58M | — | 2.50M | 4.77M |
| Long-term debt | — | — | 4.29M | 4.27M | 39.32M |
| Total debt | — | — | 4.29M | 6.77M | 44.09M |
| Total liabilities | 63.38M | 79.40M | 96.49M | 104.64M | 96.35M |
| Shareholders' equity | 49.37M | 88.56M | 41.39M | 67.06M | 113.83M |
| Net debt | — | — | -114.63M | -88.00M | -143.43M |
| Cash flow statement | |||||
| Operating cash flow | -52.79M | -36.39M | 21.55M | -68.51M | -26.01M |
| Capital expenditure | 1.02M | 1.42M | 1.37M | 708,000 | 484,000 |
| Free cash flow | -53.81M | -37.81M | 20.18M | -69.22M | -26.50M |
| Investing cash flow | -1.02M | -4.07M | 4.28M | -702,000 | -425,000 |
| Financing cash flow | -1.84M | 70.28M | -2.27M | -30.89M | 136.83M |
| Depreciation & amortization | — | — | — | — | 2.33M |
| Stock-based compensation | 4.01M | 2.54M | 3.11M | 2.87M | 6.22M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.